Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Account Payables
Amounts the company owes suppliers for goods and services received.
Sionna Therapeutics, Inc.NASDAQ: SION
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 58.0% from a year ago
Account payables stood at $2.11M at the end of Q1 FY2026, down 58.0% from a year earlier and up 174.3% from the prior quarter. Over 3 fiscal years it compounded at +11.4% a year.
Context
- Account payables amounted to 0.7% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -58.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 769K USD
- Year-over-year change
- -35.2%
- 3-year CAGR
- +11.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 769K | -35.2% |
| FY2024 | 2024-12-31 | 1.19M | +65.0% |
| FY2023 | 2023-12-31 | 719K | +29.1% |
| FY2022 | 2022-12-31 | 557K | — |
Account Payables vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 account payables of $2.11M is the lowest of the 11 companies compared; the peer median is $11.79M.
- Its year-over-year change of -58.0% is the lowest of 11, against a peer median of +55.3%.
- Account payables amounts to 0.7% of total assets for SION, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $131.86M | +10004.4% | -17.6% | 11.2% | |
| Mar 2026 | $28.2M | +105.5% | +21.0% | 5.6% | |
| Jun 2026 | $14.57M | +10.8% | +22.2% | 2.7% | |
| Sep 2026 | $13.73M | -56.8% | +19.4% | 0.9% | |
| Jun 2026 | $12.11M | -38.3% | +2.8% | 3.3% | |
| Mar 2026 | $11.47M | +80.5% | -12.6% | 2.9% | |
| Sep 2026 | $11.24M | +163.4% | -29.3% | 1.6% | |
| Sep 2026 | $4.46M | -27.4% | +11.6% | 0.9% | |
| Mar 2026 | $4.01M | +66.9% | +4.2% | 1.0% | |
| Mar 2026 | $3.38M | +43.6% | +32.0% | 0.3% | |
| Mar 2026 | $2.11M | -58.0% | +11.4% | 0.7% | |
| Peer median (excluding SION) | $11.79M | +55.3% | +7.9% | 2.1% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.